Non-Regulatory
September 24, 2018
New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Non-Regulatory
March 21, 2018
Affibody Announces First Psoriasis Patients Dosed in a Phase II Clinical Trial of ABY-035
Affibody Medical Investor Relations
Non-Regulatory
September 24, 2018
New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Non-Regulatory
March 21, 2018
Affibody Announces First Psoriasis Patients Dosed in a Phase II Clinical Trial of ABY-035